SCHEMBL25349352

SCHEMBL25349352

C[Si](C)(C)CCOCn1cc(-c2ccccc2OC(F)(F)F)c2ccc(Cl)nc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 3/20 0.37
SCN9A Q15858 4/20 0.37
S1PR1 P21453 4/20 0.34
HSD11B1 P28845 1/20 0.33
SCN5A Q14524 1/20 0.33
PDE2A O00408 1/20 0.33
PDE10A Q9Y233 1/20 0.33
TRPA1 O75762 1/20 0.32
EGFR P00533 1/20 0.32
IGF1R P08069 1/20 0.32
SRC P12931 1/20 0.32
FLT4 P35916 1/20 0.32
KDR P35968 1/20 0.32
FLT3 P36888 1/20 0.32
EPHB4 P54760 1/20 0.32
TEK Q02763 1/20 0.32
KCNN3 Q9UGI6 1/20 0.32
USP1 O94782 1/20 0.32
WDR48 Q8TAF3 1/20 0.32
SCN10A Q9Y5Y9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25347805 0.89 EGFR (0.39) DGAT1PDE10AEGFRIGF1RSRC
SCHEMBL25348390 0.87 DGAT1 (0.39) DGAT1S1PR1HSD11B1PDE10AEGFR
SCHEMBL25346684 0.85 DGAT1 (0.35) DGAT1PDE10AEGFRIGF1RSRC
SCHEMBL25346910 0.85 DGAT1 (0.34) DGAT1PDE10AEGFRIGF1RSRC
SCHEMBL25346315 0.84 BRD4 (0.36) DGAT1PDE10AEGFRIGF1RSRC
SCHEMBL25346708 0.83 DGAT1 (0.34) DGAT1PDE10AEGFRIGF1RSRC
SCHEMBL25349054 0.80 PDE10A (0.32) DGAT1PDE10AEGFRIGF1RSRC
SCHEMBL25347401 0.80 EGFR (0.37) DGAT1PDE10AEGFRIGF1RSRC
SCHEMBL29513939 0.80 EGFR (0.37) DGAT1PDE10AEGFRIGF1RSRC
SCHEMBL29514024 0.80 SCN9A (0.41) DGAT1SCN9AUSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043420-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2024-02-08 US disclosed
EP-4225741-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES Enliven Therapeutics, Inc. (US) 2023-08-16 EP disclosed
WO-2022076973-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043420-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR DGAT1 2534/4885SCN9A 3760/4885S1PR1 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.